Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

In the interconnected ASX healthcare sector it can be common for leaders to be involved in multiple companies and ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...